Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR)

Historical Holders from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
MNPR on Nasdaq
Shares outstanding
7,503,646
Price per share
$65.29
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
4,336,026
Holdings value
$354,298,233
% of all portfolios
0%
Share change
+1,159,180
Value change
+$99,764,615
Average buys %
+0%
Average sells %
-0%
Number of holders
55
Price from insider filings
$65.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 20% +1.6% $105,096,089 +$9,388,186 1,287,368 +9.8% JANUS HENDERSON GROUP PLC 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $60,644,498 +$10,020,460 742,861 +20% RA Capital Management, L.P. 30 Sep 2025
Monopar Therapeutics 13% $24,591,484 704,829 Hendricks Diane 09 Dec 2024
Adage Capital Management, L.P. 9.9% $20,905,914 599,195 Adage Capital Management, L.P. 31 Dec 2024
Tactic Pharma LLC 7.5% $18,253,536 506,199 Robinson Chandler 24 Sep 2025
As of 30 Sep 2025, Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) has 55 institutional shareholders filing 13F forms. They hold 4,336,026 shares of 7,503,646 outstanding shares (58%) .

Top 25 institutional shareholders own 57% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 17% 1,287,368 +9.8% 0.05% $105,313,139
ADAGE CAPITAL PARTNERS GP, L.L.C. 8.8% 659,195 +10% 0.09% $53,836,456
RA CAPITAL MANAGEMENT, L.P. 6.8% 511,207 0% 0.51% $41,750,276
WELLINGTON MANAGEMENT GROUP LLP 3.1% 231,463 0% $18,903,584
VANGUARD GROUP INC 2.8% 208,218 +141% 0% $17,005,165
BlackRock, Inc. 2.7% 203,751 -0.69% 0% $16,640,345
DEERFIELD MANAGEMENT COMPANY, L.P. 2.1% 159,765 0.2% $13,048,008
Saturn V Capital Management LP 2.1% 155,370 2.8% $12,689,068
TCG Crossover Management, LLC 2% 153,000 0.61% $12,495,510
ADAR1 Capital Management, LLC 1.7% 129,999 +29% 1.1% $10,617,018
Vivo Capital, LLC 1.2% 90,500 0.59% $7,391,135
GEODE CAPITAL MANAGEMENT, LLC 1.1% 84,961 -12% 0% $6,940,459
Affinity Asset Advisors, LLC 1.1% 79,483 +18% 0.6% $6,491,377
STATE STREET CORP 0.96% 72,238 +73% 0% $5,899,677
Driehaus Capital Management LLC 0.86% 64,636 0.04% $5,278,822
Ally Bridge Group (NY) LLC 0.86% 64,455 +87% 4.4% $5,264,040
NORTHERN TRUST CORP 0.36% 26,855 -16% 0% $2,193,247
Bank of New York Mellon Corp 0.23% 17,170 +92% 0% $1,402,260
MORGAN STANLEY 0.21% 15,711 +98% 0% $1,283,118
BARCLAYS PLC 0.2% 15,082 +107% 0% $1,231,747
Informed Momentum Co LLC 0.19% 14,629 0.14% $1,194,750
Alyeska Investment Group, L.P. 0.16% 12,215 0% $997,599
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.16% 11,797 -11% 0% $963,461
UBS Group AG 0.11% 7,973 -64% 0% $651,154
MILLENNIUM MANAGEMENT LLC 0.1% 7,334 -50% 0% $598,968

Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 14 $914 +$196 $65.29 1
2025 Q3 4,336,026 $354,298,233 +$99,764,615 $81.67 55
2025 Q2 3,176,497 $113,304,454 +$10,313,027 $35.78 43
2025 Q1 2,886,019 $109,374,138 +$11,536,778 $36.41 34
2024 Q4 2,578,295 $57,125,546 +$56,777,792 $22.00 18
2024 Q3 15,707 $105,865 +$105,864 $6.74 6